WHO Approves First Malaria Treatment Made for Infants

For decades, doctors treating malaria in newborns faced an impossible choice. They had to guess at scaled-down doses of adult medicines, risking dangerous errors with every sick baby.

That era just ended. The World Health Organization has approved the first malaria treatment designed specifically for infants weighing between 4.4 and 11 pounds.

The treatment uses artemether-lumefantrine, a proven malaria fighter, but reformulated for the smallest patients. Governments and health agencies worldwide can now order this quality-assured medicine made just for babies.

"This addresses a group that has remained underserved in malaria care," the WHO announced. Until now, giving infants adjusted doses of children's medicine increased the risk of side effects and dosing mistakes that could prove fatal.

The timing couldn't be more critical. Malaria caused 282 million cases and 610,000 deaths in 2024, with children under five accounting for most fatalities. Africa bears the heaviest burden.

The Ripple Effect

This breakthrough arrives alongside three new rapid diagnostic tests that catch malaria cases older tests miss. Some parasite strains have evolved to hide from standard detection, but these new tests find them anyway.

WHO Director-General Tedros Adhanom Ghebreyesus called the combined advances a strengthening of the global malaria response. Vaccines, better diagnostics, and now age-appropriate treatments are working together to protect the most vulnerable.

The fight against malaria has slowed in recent years due to drug resistance, funding gaps, and detection challenges. But since 2000, billions of infections have been prevented through steady progress.

Now the tiniest patients finally have medicine made for them, turning guesswork into precision care that could save thousands of young lives.